Coronavirus Outbreak: WHO pauses trial of hydroxychloroquine over safety concerns, clinical tests of other potential treatments to continue
The World Health Organization has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns
Geneva: The World Health Organization (WHO) has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.
Hydroxycholoroquine has been touted by Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus . The US President has said he was taking the drug to help prevent infection.
“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board,” Tedros told an online briefing.
He said the other arms of the trial - a major international initiative to hold clinical tests of potential treatments for the virus - were continuing.
The WHO has previously recommended against using hydroxychloroquine to treat or prevent coronavirus infections, except as part of clinical trials.
Dr Mike Ryan, head of the WHO emergencies programme, said the decision to suspend trials of hydroxychloroquine had been taken out of “an abundance of caution”.
This year's hajj, with participants chosen through a lottery, is larger than the pared-down version staged in 2020 but drastically smaller than in normal times
The organisation said overall 3.4 million new COVID-19 cases were reported in the week to 18 July, which is a 12 percent increase from the week before
WHO on Covaxin: The Bharat Biotech vaccine has demonstrated 77.8% effectiveness against symptomatic COVID-19 and 65.2% protection against the B.1.617.2 Delta variant